| Product Name | Enfuvirtide |
| Synonyms | Fuzeon, T-20, DP-178, ENF, Pentafuside, gp41(127-162) |
| CAS Number | 159519-65-0 |
| Sequence (3-Letter) | Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH₂ |
| Sequence (1-Letter) | Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH₂ |
| Molecular Formula | C₂₀₄H₃₀₁N₅₁O₆₄ |
| Molecular Weight | 4492 (≈ 4491.88) |
| Category | Drug Peptide – HIV Fusion Inhibitor |
| Purity | ≥98% (by HPLC) |
| Appearance | White to off-white amorphous powder |
| Counter Ion | TFA or acetate (salt form per specification; TFA-free available) |
| Peptide Content | ≥80% (per specification) |
| Solubility | Limited solubility in pure water; soluble in aqueous buffers near neutral pH |
| Storage | -20°C, desiccated, protected from light |
| Available Scale | mg – kg (research quantities to scale-up batches) |
| QC Documentation | COA, HPLC, MS identity (additional API/regulatory documentation on request) |
| Usage | For research and pharmaceutical development use, and as a reference standard or active pharmaceutical ingredient for manufacturing. Not for human or veterinary use; not for sale to patients. Any therapeutic use is subject to applicable regulatory approval. |
Enfuvirtide is a synthetic 36-amino-acid peptide and an HIV-1 fusion inhibitor, known as a medicine under the brand name Fuzeon and by the code T-20 (CAS 159519-65-0). Its sequence, Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2, is taken from a region of the HIV-1 protein gp41, with an acetylated N-terminus and a C-terminal amide. We supply it as a white powder for research and pharmaceutical development.
Enfuvirtide blocks the last step by which HIV-1 enters a cell. To get into a CD4 cell, the viral protein gp41 has to fold into a six-helix bundle that pulls the virus and cell membranes together. Enfuvirtide is a copy of part of gp41, so it binds the other part and gets in the way, preventing that bundle from forming and stopping the virus from fusing with the cell.
Clinically, enfuvirtide is used together with other antiretroviral drugs to treat HIV-1 infection, especially in people whose virus has become resistant to other drug classes. This is background information only; the material we supply is for research and pharmaceutical manufacturing use, and is not for human or veterinary use and not for sale to patients.
We supply Enfuvirtide with a certificate of analysis, HPLC purity data, and mass-spec identity confirmation. Additional documentation for API and regulatory work is available on request, and salt form and purity can be set to your specification.
Yes. We manufacture Enfuvirtide in-house and supply from research quantities up to scale-up batches. As a 36-residue peptide it is a demanding synthesis, and we can discuss the right approach for your scale. Contact us with your required purity and quantity for a quote.
Enfuvirtide is a synthetic 36-amino-acid peptide and an HIV-1 fusion inhibitor, the first drug of its class. It is known as a medicine under the brand name Fuzeon and by the development code T-20. We supply it as a raw material for research and pharmaceutical development.
Enfuvirtide is a linear 36-residue peptide with the sequence Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2, built entirely from natural L-amino acids, with an acetylated N-terminus and a C-terminal amide. Its sequence is taken from a heptad-repeat region of the HIV-1 envelope protein gp41. Its CAS number is 159519-65-0, its molecular formula is C204H301N51O64, and its molecular weight is about 4492.
HIV-1 enters a CD4 cell by fusing its envelope with the cell membrane. In that step the viral protein gp41 folds into a six-helix bundle that draws the two membranes together. Enfuvirtide reproduces part of gp41 and binds the complementary heptad-repeat region, blocking formation of the six-helix bundle. With the bundle blocked, the virus cannot complete fusion and cannot enter the cell, which is why the class is called fusion or entry inhibitors.
Enfuvirtide is used clinically together with other antiretroviral drugs to treat HIV-1 infection, particularly in people whose virus has become resistant to other classes of antiretroviral. This information is provided as scientific and reference background only. The material supplied by SynPeptide is intended for research and pharmaceutical manufacturing, is not for human or veterinary use, and is not for sale to patients; any therapeutic use is subject to applicable regulatory approval.
At 36 residues, enfuvirtide is one of the larger peptides made by chemical synthesis and is a well-known test of large-scale peptide manufacturing. We supply it with a certificate of analysis, HPLC purity data, and mass-spectrometry identity confirmation, with further documentation available to support active pharmaceutical ingredient and regulatory work, and purity and salt form set to your specification.
We manufacture Enfuvirtide by solid-phase synthesis and supply it from research quantities through to scale-up batches. For related capabilities, see drug peptides, custom peptide synthesis, large-scale peptide synthesis, and our peptide CDMO services. Material is supplied for research and pharmaceutical manufacturing use only.
